Solanes, Aleix http://orcid.org/0000-0002-2491-200X
Mezquida, Gisela
Janssen, Joost
Amoretti, Silvia http://orcid.org/0000-0001-6017-2734
Lobo, Antonio http://orcid.org/0000-0002-9098-655X
González-Pinto, Ana
Arango, Celso http://orcid.org/0000-0003-3382-4754
Vieta, Eduard
Castro-Fornieles, Josefina http://orcid.org/0000-0003-0632-2687
Bergé, Daniel
Albacete, Auria
Giné, Eloi http://orcid.org/0000-0002-3130-5566
Parellada, Mara
Bernardo, Miguel http://orcid.org/0000-0001-8748-6717
Bioque, Miquel
Morén, Constanza
Pina-Camacho, Laura
Díaz-Caneja, Covadonga M.
Zorrilla, Iñaki
Corres, Edurne Garcia
De-la-Camara, Concepción
Barcones, Fe
Escarti, María José
Aguilar, Eduardo Jesus
Legido, Teresa
Martin, Marta
Verdolini, Norma
Martinez-Aran, Anabel
Baeza, Immaculada
de la Serna, Elena
Contreras, Fernando
Bobes, Julio
García-Portilla, María Paz
Sanchez-Pastor, Luis
Rodriguez-Jimenez, Roberto
Usall, Judith
Butjosa, Anna
Salgado-Pineda, Pilar
Salvador, Raymond
Pomarol-Clotet, Edith
Radua, Joaquim
,
Article History
Received: 10 June 2022
Accepted: 28 October 2022
First Online: 17 November 2022
Competing interests
: Dr. Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of AB-Biotics, Adamed, Angelini, Casen-Recordati, Janssen-Cilag, Menarini, Rovi, and Takeda. Dr. C. De-la-Camara received financial support to attend scientific meetings from Janssen, Almirall, Lilly, Lundbeck, Rovi, Esteve, Novartis, AstraZeneca, Pfizer, and Casen-Recordati. CDC has received honoraria from Sanofi and Exeltis. Dr. Parellada has received educational honoraria from Otsuka, research grants from Instituto de Salud Carlos III (ISCIII), Ministry of Health, Madrid, Spain, has received grant support from ISCIII, Horizon2020 of the European Union, CIBERSAM, Fundación Alicia Koplowitz, and Mutua Madrileña and travel grants from Otsuka, Exeltis and Janssen; she has served as a consultant for Servier, Exeltis, Fundación Alicia Koplowitz, and ISCIII. LPC has received honoraria or grants unrelated to the present work from Rubió, Rovi, and Janssen. Dr. R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/BMD-2422 AGES; S2017/BMD-3740), Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen-Recordati, Angelini. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr. Vieta has received grants and served as a consultant, advisor, or CME speaker for the following entities (work unrelated to the topic of this manuscript): AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Galenica, Janssen, Lundbeck, Novartis, Otsuka, Sage, Sanofi-Aventis, and Takeda. The remaining authors report no financial relationships with commercial interests.